Prof. Martin T. Rothman
Cardiologist & VP Medical Affairs Medtronic
Co-Founder of CorFlow Therapeutics AG, Chief Medical
Officer and VP of Medical Affairs, Medtronic Coronary, RDN
& Structural Heart, Santa Rosa, CA, USA, Honorary Professor
of Interventional Cardiology, Queen Mary, University of London, United Kingdom
Martin is a world-renown and NHS pioneer in interventional cardiology and
has founded numerous cardiology medical device companies raising more than
£300M for these early stage companies. He joined Medtronic in 2010 and is
now responsible for a wide product spectrum from coronary&vascular disease to resistant
hypertension and minimally invasive heart valves.
Rick is the Founder and Chief Executive Officer of Cyrano Therapeutics,
a private company that has developed a treatment to restore the sense of smell and flavor in those who have lost it.
He is also a member of the Executive Committee and the Board of Directors for MDIC, the Medical Device Innovation Consortium,
Chairman of Aventamed and Vice Chairman of The Mullings Group. Further board positions include SoundBite Medical Solutions and Cardiac Implants.
Rick has more than 35 years of management experience in the medical device industry with more than 30 years in the cardiovascular device space.
Rick has previously led the company foundation for four medical device companies:
Mitralign (acquired by Edwards), CircuLite (acquired by HeartWare), FlowMedica (acquired by Angiodynamics)
and X-Cell and guided the recapitalization and redirection of two other successful medical device companies:
Impella (acquired by Abiomed) and Pathway (acquired by Bayer). Mr. Geoffrion has served as the Chairman of Impella CardioSystems AG, CircuLite and FlowMedica, Inc..
He received a BSME and an MBA from the University of Connecticut.
Gunnar M. Páh
Gunnar has over 40 year’s experience in medical device distribution, start-ups and financing.
He started as a sales manager in Medico (Oslo, Norway) and has founded successful distribution
companies in Europe (Medi-Stim AS (1984), CardioMed GmbH (1994) and MicroMed (1994)).
Gunnar is an active early stage investor in several breakthrough interventional
cardiology companies of which many have had a successful exit: AVE, Vascular Science,
Atritech, Embolic Protection, Rubicon, Sapheon, Loma Vista, CoreValve and CardiAQ.
Erik is the chairman and founder of NeoMed Management and was previously the chairman and controlling
shareholder of NeoMed AS, providing investment advisory services, specializing in small and medium sized
companies in the pharmaceutical, medical device and diagnostic industries. Erik has served as a board member
of a. o. Clavis Pharma AS (which went public on the Oslo Stock Exchange), GenoVision AS (sold to Qiagen),
Thommen Medical AG (investment sold in a private secondary sale) and Vessix Vascular Inc. (sold to Boston Scientific
Corporation), and currently serves on the Board of Directors of Axonics Modulation Technologies Inc. (USA), JenaValve
Technology Inc. (USA, Germany), Sequana Medical AG (Switzerland) and Sonendo Inc. (USA). Erik is a founder and former
chairman of the Norwegian Venture Capital Association. He holds a Dr. Scient. degree in organic chemistry from the University
of Oslo and a Master of Science degree in Management from the Graduate School of Business, Stanford University, USA.